COMP <GO>
XNCR vs PVLA // EV/EBITDA & P/E VALUATION
Xencor Inc. (NASDAQ) VS. Palvella Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: XNCR 3
— PVLA 2
■ METRIC PARITY
LAST: $29.21 (-2.60%) • MKT CAP: $2.17B
valuation
—
LAST: $151.58 (+2.79%) • MKT CAP: $2.18B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XNCR VS. PVLA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XNCR | PVLA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.30% | -27.90% | +6.60 | XNCR | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.37% | -1.14% | -5.23 | PVLA | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 13.70% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.32 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 2/9 | +2.00 | XNCR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.0 | 59.5 | +8.42 | XNCR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.17B | $2.18B | -$12.2M | PVLA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XNCR REV | PVLA REV | XNCR GROSS % | PVLA GROSS % | XNCR FCF | PVLA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $125.6M | $0 | — | — | -$138.3M | -$25.0M |
| FY 2024 | $110.5M | $0 | — | — | -$208.3M | -$10.8M |
| FY 2023 | $174.6M | $42.8M | — | — | -$77.9M | -$13.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XNCR // BETA —
PVLA // BETA —